Reagent is required to perform all testing which provide healthcare providers with critical information in the detection/management of allergic reactions for SAN antonio market and 153 other…
Ended Awarded
- Contract number
- HT009025FG30034
- Awardee
-
Phadia US Inc. UEI DK4EVCWUNUM4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $74,946
Award facts
- Contract value 100% obligated
- $74,945.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Portage, MI 49002, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a Blanket Purchase Agreement call valued at $74,945.52 to Phadia US Inc.'s Immunodiagnostics Division on August 22, 2025, with completion targeted for September 30, 2025. Under this firm fixed-price contract, Phadia will supply reagents and conduct allergy testing services for San Antonio Military Medical Center and 153 additional military treatment facilities across the Department of Defense. This testing provides critical diagnostic information to healthcare providers for detecting and managing allergic reactions among service members and beneficiaries. The contract was awarded through open market procurement with no set-aside designation and will be performed from the vendor's facility in Portage, Michigan.
Phadia US Inc., a foreign-owned subsidiary of Thermo Fisher Scientific, specializes in advanced immunodiagnostic testing solutions and has established itself as a key supplier to military medical facilities. The company maintains two significant Indefinite Delivery/Indefinite Quantity Blanket Purchase Agreements valued at $13.8 million each with Air Force Air Education and Training Command through April 2026, which support procurement of IMMUNOCAP System analyzers and related equipment. This current Defense Health Agency award reflects the vendor's strategic importance in supporting immunodiagnostic capabilities across the military healthcare system, enabling consistent access to specialized allergen-specific immunoglobulin E antibody testing that supports allergy diagnosis and management protocols.
Description
Reagent is required to perform all testing which provide healthcare providers with critical information in the detection/management of allergic reactions for SAN antonio market and 153 other military treatment facilities.
Quick answers
Who was awarded contract HT009025FG30034?
HT009025FG30034 was awarded to Phadia US Inc. by Defense Health Agency (Department of Defense) on August 22, 2025.
How much is contract HT009025FG30034 worth?
The government has obligated $74,946 on HT009025FG30034.
Is contract HT009025FG30034 an order under another contract?
Yes. HT009025FG30034 is a BPA call under FA301624A0046, a blanket purchase agreement.
Was contract HT009025FG30034 competed?
The extent of competition for HT009025FG30034 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award